The results are in: Eli Lilly's (NYSE: LLY) experimental insulin, peglispro, is superior to Sanofi's (NYSE: SNY) flagship Lantus franchise.
Three late stage studies showed that Lilly's new drug controlled blood sugar and weight gain better than the current market leader. However, despite these tremendous results, Eli Lilly's victory may prove hollow. The specter of liver toxicity may hamper the peglispro's ability to get approved and depress consumer demand if and when it hits the market.
In this video, Motley Fool health care analyst David Williamson discusses the positive and negatives of Eli Lilly's trial results, why sales could be tough to come by, and when investors can expect further action around this drug.
Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
The article Will Eli Lilly's Groundbreaking Diabetes Victory Prove Hollow? originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.